ACAMBIS
Acambis plc, a biotechnology company, engages in the research, development, and manufacture of vaccines for the prevention and treatment of infectious diseases in Europe and North America. The company offers ACAM2000, a smallpox vaccine for emergency-use stockpiling; and ChimeriVax-JE, a single-dose Japanese encephalitis vaccine for endemic markets and travelers. Its products in pipeline also includes ChimeriVax-West Nile, a Phase II clinical trial candidate against West Nile virus and North Ame... rica's endemic mosquitoborne encephalitis; and acam-flu-a, a Phase I clinical trial candidate against influenza vaccination and pandemic influenza. In addition, the company's products comprise ACAM-CdifF, a Phase I trial vaccine in clinical development against hospital-acquired infection; Herpes Simplex Virus against sexually transmitted infections; and ChimeriVax-Dengue, an advanced Phase II trial vaccine against the haemorrhagic fever. Acambis plc was formerly known as Peptide Therapeutics Group PLC and changed its name to Acambis plc in December, 2000. The company was founded in 1992 and is based in Cambridge, United Kingdom. As of September 25, 2008, Acambis plc operates as a subsidiary of Sanofi Pasteur SA.
ACAMBIS
Industry:
Biotechnology
Founded:
1992-01-01
Address:
Cambridge, Cambridgeshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.acambis.com
Total Employee:
101+
Status:
Closed
Contact:
44 12 2327 5300
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF LetsEncrypt Content Delivery Network Font Awesome Apache JsDelivr BootstrapCDN
Similar Organizations
Enzyvant Sciences
Enzyvant Sciences is a biotechnology company which focuses on developing treatments for rare diseases.
More informations about "Acambis"
Acambis - Crunchbase Company Profile & Funding
Acambis plc, a biotechnology company, engages in the research, development, and manufacture of vaccines for the prevention and treatment of infectious diseases in Europe and North America.See details»
Acambis plc - Crunchbase Company Profile & Funding
Acambis plc is a Biotechnology company. There is no recent news or activity for this profile.See details»
Acambis plc - Cambridge, United Kingdom - bionity.com
Feb 27, 2008 Acambis plc, a biotechnology company, engages in the research, development, and manufacture of vaccines for the prevention and treatment of infectious diseases in Europe …See details»
Acambis Company Profile | Management and Employees List
Acambis Profile and History. Acambis is a leading vaccine company developing novel vaccines that address significant unmet medical needs or substantially improve standards of care.See details»
Acambis Company Profile 2024: Valuation, Investors, Acquisition
Information on acquisition, funding, investors, and executives for Acambis. Use the PitchBook Platform to explore the full profile.See details»
Sanofi Pasteur Biologics (formerly Acambis) - Virtual Biosecurity …
“Sanofi Pasteur, the vaccines division of sanofi-aventis Group, is the largest company in the world devoted entirely to human vaccines.” Sanofi Pasteur Biologics Co. (formerly Acambis), …See details»
Acambis - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Acambis is a biotechnology company developing vaccines to treat infectious diseases in Europe and North America.See details»
Acambis - Products, Competitors, Financials, Employees, …
" Related Stories Seqirus announces FDA approval of Fluad for seasonal influenza According to the World Health Organization, about half of the world's population is at risk of developing …See details»
Acambis Company Profile | Canton, MA - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Acambis of Canton, MA. Get the latest business insights from Dun & Bradstreet.See details»
Sanofi Pasteur acquires Acambis for GBP285 million
Acambis’s skilled workforce of individuals who share our passion for vaccines and prevention of infectious diseases will contribute to our efforts in answering unmet medical needs of people …See details»
Sanofi-Aventis to complete Acambis deal - Financial Times
Sep 24, 2008 Sanofi-Aventis, the French pharmaceutical group, is set to complete its acquisition of Acambis of the UK on Thursday, with plans to keep the vaccine developer partly …See details»
Sanofi Pasteur Completes the Acquisition of Acambis
Sep 25, 2008 We look forward to welcoming them into Sanofi Pasteur's organization and joining us in writing new pages of vaccine history." Sanofi Pasteur was already developing three …See details»
Acambis Inc. Company Profile | Cambridge, MA - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Acambis Inc. of Cambridge, MA. Get the latest business insights from Dun & Bradstreet.See details»
Acambis - Crunchbase
Acambis is a biotechnology company developing vaccines to treat infectious diseases in Europe and North America.See details»
Sanofi-Aventis to buy Acambis for about $549.5 mln
SAN FRANCISCO (MarketWatch) -- Sanofi Pasteur Holding, a vaccines division of Sanofi-Aventis , will buy United Kingdom's Acambis PLC for a total of about 276...See details»
Sanofi to acquire Acambis for $546M - Fierce Biotech
Jul 25, 2008 More evidence that the vaccine market is hot: vaccine maker Acambis has agreed to a £276 million ($546 million) by Sanofi-Pasteur, the vaccines division of France's Sanofi …See details»
Acambis Inc. - Cambridge, Massachusetts (MA) @ BiosciRegister.com
Profile: Acambis Inc. is a vaccine company developing novel vaccines that address significant unmet medical needs.Our ACAM2000® vaccine is a live, vaccinia virus smallpox vaccine for …See details»
Sanofi closes deal on Acambis | Fierce Pharma
Sep 25, 2008 Sanofi-Aventis closes on its deal to buy Acambis today, but it's working hard to avoid losing the entrepreneurial spirit that attracted the French pharma company to the …See details»
Sanofi makes $548M deal for Acambis - Fierce Pharma
Jul 28, 2008 Sanofi Pasteur has inked a deal to buy vaccine-maker Acambis for about $548 million (£276 million), a 64 percent per-share premium. The two companies had already been …See details»
Sanofi buys into Acambis' West Nile vaccine program
Nov 13, 2007 Sanofi Pasteur is buying into Acambis' program for a novel West Nile vaccine. Acambis snares $10 million up front with $70 million in development and sales milestones.See details»